GlassScriptPhysician profile
Jacob R Rash
NPI 1104321462
$721.24
in general payments reported to CMS, 2019-2025
14 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $146 · 2023: $199 · 2024: $156 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $187.41 | 2022-2023 | Arista Ah Flexitip |
| Allergan, INC. | $99.64 | 2022 | |
| Urogen Pharma, INC. | $90.61 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $61.43 | 2024 | Capvaxive, Keytruda, Gardasil |
| Ferring Pharmaceuticals INC. | $49.41 | 2023 | Rebyota |
| Pfizer INC. | $44.71 | 2024-2025 | |
| Janssen Biotech, INC. | $44.31 | 2025 | Erleada |
| Teleflex LLC | $40.78 | 2025 | Quikclot |
| Exact Sciences Corporation | $27.00 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $22.18 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $17.05 | 2024 | Airsupra |
| Melinta Therapeutics, LLC | $15.11 | 2025 | Kimyrsa, Orbactiv |
| Pacira Pharmaceuticals Incorporated | $13.57 | 2025 | Exparel |
| Endogastric Solutions, INC | $8.03 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Rash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.